How to Reduce — Chemotherapy Costs

Yes — your oncologist can prescribe by the international nonproprietary name of the molecule rather than a specific brand. Some oncologists write a brand name by habit, not because the brand is clinically required. Asking them to prescribe generically is a reasonable and common request. Bring it up before your next cycle begins, not on the day of the infusion, so there is time to confirm availability at the dispensing pharmacy.

For standard chemotherapy molecules, generic versions are chemically identical to the originator and approved by CDSCO using the same standards. For biologics and targeted therapies, the version is called a biosimilar, and it has gone through its own regulatory approval process in India. Neither term means lower quality — it means the patent has expired or the manufacturer met the approval threshold by a different route. Ask your oncologist which category each of your medicines falls into.

You can check PMJAY eligibility at any empanelled hospital by presenting your Aadhaar number — no prior paperwork is needed. Most CION centres have a dedicated executive who can run the check while you are on site. Aarogyasri covers residents of Telangana and Andhra Pradesh; eligibility and the list of covered procedures are managed through the respective state health authority. Do this at your first visit, before the first cycle, because schemes cannot usually be applied to bills already paid.

Day-care chemotherapy is safe for the vast majority of standard regimens and is the setting recommended in ASCO and NCCN guidance when patients are medically stable. You receive your infusion under nursing supervision, your vitals are monitored throughout, and you are observed for any early reaction before discharge. Inpatient admission is reserved for regimens that require overnight monitoring, patients with specific complications, or cases where travel makes same-day discharge impractical. Ask your oncologist whether your regimen qualifies.

For standard chemotherapy molecules, yes — asking for a CDSCO-approved generic when one is prescribed is straightforward. For biologics and targeted therapies, switching to a biosimilar involves a clinical judgment your oncologist needs to make, because not all are interchangeable without a review. The clearest way to open this conversation is to ask: 'What is the generic or international name of each medicine in my regimen, and is an approved generic available?' Your team can then tell you which switches are straightforward and which need discussion.

Tell your oncologist directly — this is a clinical conversation, not just a financial one. Several routes exist that are only explored when the team knows cost is the problem: compassionate access programs run by some pharmaceutical companies, referral to a government hospital where the regimen is dispensed at no charge, scheme linkages not explored at the first visit, and occasionally a switch to a regimen that is clinically comparable but less expensive. None of these can be offered if your team does not know cost is a barrier.